P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Subramaniam S, Toner G, Stockler M, Martin A, Pashankar F, Tran B, Jeffery M, Mazhar D, Huddart R, Walpole E, Stevanovic A, Wyld D, Hanning F, Wheater M, Balagtas J, Troon S, Birtle A, White J, Grimison P. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2021, 39: tps390-tps390. DOI: 10.1200/jco.2021.39.6_suppl.tps390.Peer-Reviewed Original ResearchMetastatic germ cell tumorsPoor-risk metastatic germ cell tumoursGerm cell tumorsStandard BEPComplete responseStage IInternational randomized phase III trialRandomized phase III trialStandard first-line chemotherapyCisplatin 20mg/Standard BEP chemotherapyBaseline blood samplesFirst-line chemotherapyPhase III trialsProgression-free survivalTrial of chemotherapyD1-5Post-chemotherapy treatmentClinical trial informationTranslational substudyBEP chemotherapyOpen labelPrimary endpointStandard regimensFree survival